NASDAQ · STOCK
Vertex Pharmaceuticals
$485.36
52W $362.50 – $533.67
55/100
$115.02B
30.0
0.29
Price History (6M)
Executive Summary
7 analysts weighed in with 57% agreement on a neutral lean. Portfolio Manager: Portfolio position concentration is currently healthy. Overall recommendation: BUY.
Bull & Bear Case
Bull Case
- Daily trend: uptrend.
- Daily uptrend conflicts with weekly downtrend — buying against the higher timeframe trend is higher risk.
- Daily volatility (ATR%) above ~3% is treated as elevated risk.
Bear Case
- MACD histogram is negative (-0.409) — bearish momentum.
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Bearish candlestick pattern(s) detected: Three Black Crows.
- Risk/reward is unfavorable: 5.5% downside vs 0.4% upside.
AI Investment Committee
Committee Consensus
As of July 11, 2026
Overall Committee Score
55/100
Agreement
50%
Analysts
6
Conviction
Contested
Value Analyst
neutral
54
/ 100 · High confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 23.9% shows genuine earnings power backing the valuation
− P/E of 27.9 is moderate-to-rich
Growth Analyst
neutral
50
/ 100 · Moderate confidence
Moderate growth -- present but not remarkable
− Growth rate is decelerating quarter over quarter -- the trend line matters more than the level
Technical Analyst
neutral
49
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst
neutral
58
/ 100 · Moderate confidence
Moderate risk -- no single red flag, but nothing that clearly de-risks the position either
+ Low leverage (debt-to-equity 0.01) -- balance sheet can absorb a shock
− Bollinger bandwidth of 22.4% signals elevated volatility
Macro Analyst
bullish
70
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst
bullish
66
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.27 across 96 articles, 14d)
Portfolio Manager
bullish
75
/ 100 · Low confidence
The existing book is healthy enough that position-sizing here is a matter of stock selection, not portfolio constraints
+ Portfolio position concentration is currently healthy
Technical Analysis
RSI (14)
43.8
Neutral
MACD Histogram
-0.409
Bearish Momentum
Trend Direction
Uptrend
Weekly: Downtrend
Market Structure
Mixed
Support
$458.47
Resistance
$487.39
Bollinger %B
0.53
Inside Bands
Price vs Moving Averages
EMA 9
$498.40
Below
EMA 21
$484.55
Above
EMA 50
$466.13
Above
EMA 200
$452.02
Above
Fundamental Analysis
Valuation
34
Growth
49
Profitability
100
Financial Health
100
Valuation
P/E Ratio
30.0×
P/B Ratio
6.16×
PEG Ratio
—
Dividend Yield
—
52W High
$533.67
52W Low
$362.50
Quality & Growth
ROE
2393.0%
ROA
1718.0%
Gross Margin
8624.0%
Operating Margin
3831.0%
Revenue Growth YoY
+1008.0%
Debt / Equity
0.01
AI Fundamental Assessment
P/E ratio of 30.0 (rich relative to a 15-40x range); Price-to-book of 6.2x; Revenue growth (YoY) of 10.1%; Return on equity of 23.9%; Return on assets of 17.2%; Net margin of 35.5%; Gross margin of 86.2%; Current ratio of 2.90 (healthy short-term liquidity); Debt-to-equity of 0.01; Most recent quarter beat estimates by 1.7%; EPS growth decelerating (+4.8% -> -11.1% QoQ); Analyst estimates falling over recent quarters
Key Risks
- MACD histogram is negative (-0.409) — bearish momentum.
- Weekly trend is bearish while daily is bullish — against the higher-timeframe trend.
- Bearish candlestick pattern(s) detected: Three Black Crows.
- Risk/reward is unfavorable: 5.5% downside vs 0.4% upside.
This risk summary is generated from quantitative data signals, not qualitative opinion. All investors should conduct their own due diligence. This is not financial advice.
Get the Full VRTX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Mobile